-

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2025 financial results and provide a business update.

A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross, CFA – Investors
investor_relations@gilead.com

Industry:

Gilead Sciences, Inc.

NASDAQ:GILD
Release Versions
English
Hashtags
#Earnings
#GILD
#GileadInvestorRelations
#GileadSciences
#QuarterlyResults
#Results

Contacts

Jacquie Ross, CFA – Investors
investor_relations@gilead.com

Social Media Profiles
Gilead Sciences Facebook
Gilead Sciences Instagram
Gilead Sciences LinkedIn
Gilead Sciences YouTube
More News From Gilead Sciences, Inc.

Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards®

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new collaboration with TelevisaUnivision and the 27th Latin GRAMMY Awards that will bring HIV prevention awareness into one of the most prominent cultural moments for Latino audiences. The collaboration comes at a crucial time for Latino communities in the United States. In 2024, Hispanic/Latino people were 67% more likely than the U.S. population overall to be diagnosed with HIV, with a diagnosis rate...

New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)--New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention...

Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi® (seladelpar) achieved the alkaline phosphatase (ALP) normalization composite endpoint defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥ 15% decrease from baseline. ALP is a key marker of disease activity and long-term outcomes in PBC. The...
Back to Newsroom